business
Lilly’s One-Time Cholesterol Shot
Eli Lilly is developing a groundbreaking one-time gene-editing treatment that could permanently lower bad cholesterol and reduce heart disease risk. Bloomberg's Madison Muller joins Open Interest to break down the science, the risks, and why Lilly is racing to expand beyond obesity drugs into its ne
Read full story on Bloomberg Markets → More top storiesAlso covered by
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop